Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Testicular Neoplasms 2Neoplasms 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Seminoma 1Oropharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Medulloblastoma 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Hearing Loss 1Carcinoma 1Anosmia 1Adenocarcinoma 1

Interventions

Cisplatin 12Etoposide 11Carboplatin 9Paclitaxel 7Ifosfamide 7Filgrastim 7Bleomycin 6Radiotherapy 5Magnetic Resonance Spectroscopy 4pegfilgrastim 3Peripheral Blood Stem Cell Transplantation 3liposomal amphotericin B 2Therapeutics 2Platinum 2Ipilimumab 2Imatinib Mesylate 2Granulocyte Colony-Stimulating Factor 2Cyclophosphamide 2CTLA-4 Antigen 2tremelimumab 1sodium thiosulfate 1sargramostim 1lerisetron 1ixabepilone 1etoposide phosphate 1durvalumab 1cabozantinib 1aldesleukin 1Vinblastine 1Thiotepa 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Seminoma × Hearing × Clear all
NCT07218913 2026-04-17

Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors

City of Hope Medical Center

Phase 1 Recruiting
44 enrolled
Genitourinary

Testicular Neoplasms, Seminoma, Hearing Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡